The customer wanted to conduct a market impact analysis to identify patient groups eligible for its new soon-to-be-launched second- and third-line colorectal cancer (CRC) treatments
They also wanted to calculate the percentage of additional patients who could potentially move from Best Supportive Care (BSC) treatment to second and third-line treatments, making them eligible for the company’s new drug
We conducted a launch impact study using analog benchmarking models to compare similar drugs approved and provide a projection of the patient pool, thus estimating the new drug's peak share at launch. We also assessed the relative safety profiles to estimate the redistribution of patients across treatment lines. The benchmark analysis helped identify potential new patient groups arising from the discontinuation of 2 existing generic drugs due to safety concerns and updated labelling.
The percentage of patients currently under BSC were identified as prospects for the company’s new second- and third-line CRC treatment. They also found that patients who were previously kept under the discontinued treatments were likely to return to BSC, making them eligible for the new treatment.